Are ZURA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ZURA leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / ZURA / insiders

PROK (35) TECX (30) TRXB (48) AUTL (21) ⌘ Pro Terminal →

Zura Bio Limited (Class A) (ZURA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.94 -2.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.91

Zura Bio Limited (Class A) (ZURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $389.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZURA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Zura Bio Limited (Class A) (NASDAQ: ZURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $3.94 (-2.47% 1D, market cap $389.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZURA ranks #830 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZURA compare to PROK and TECX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ZURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $391.6M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, ZURA leads on earnings multiple (N/A) while ZURA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZURA?

▼

Per ZURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855644), Zura Bio Limited (Class A) generated $210.7M in revenue (+36.3% YoY), -$68.7M in net income, and -$64.9M in free cash flow against $113.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.92 (-0.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZURA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY ZURA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (21% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.23-5.4% Next Q

Q2 (-2Q)

Grade E$4.00+6.7% Next Q

Q3 (-1Q)

Grade E$4.27-7.7% Next Q

Current

Grade E$3.94-9.8% Hist 90D α

Trajectory: E (37) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.58) and Max Pain ($4.14) forces dealer call-delta covering toward $7.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ZURA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ZURA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ZURA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZURA)

✓Walkthrough of ZURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.94%📐 HORIZONTAL RANGE

2026-11-03O $3.85H $4.04L $3.85C $3.94VOL 4.08M

RES: $8.48SUP: $3.12SMA50: $4.58SMA200: $5.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZURA Butterfly Map → + Track ZURA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZURA)

Health Care Rank #830 of 1016 ⚔️ PROK vs ZURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZURA vs. PROK, TECX, TRXB, AUTL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zura Bio Limited (Class A) (ZURA) ranks #830 by composite RQD confidence (29/100, grade E) and #478 by equity capitalization ($389.2M). Within this direct 5-issuer industry benchmark cohort, ZURA leads on earnings valuation at N/A trailing P/E, while ZURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with ZURA at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZURA ACTIVE Zura Bio Limited (Class A)	E	29/100	—	—	-35.0%	-2.47%	$389.2M	Benchmark Subject
PROK ProKidney Corp. (Class A)	D-	35/100	—	—	-35.0%	-13.51%	$391.6M	/prok-vs-zura →
TECX Tectonic Therapeutic Inc.	E	30/100	—	—	-35.0%	-4.04%	$386.7M	/tecx-vs-zura →
TRXB TRex Bio Inc.	D	48/100	—	—	—	-0.73%	$377.1M	/trxb-vs-zura →
AUTL Autolus Therapeutics plc	E	21/100	—	-27.8%	-35.0%	-6.58%	$404.6M	/autl-vs-zura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zura Bio Limited (Class A) (ZURA) reported GAAP revenue of $210.7M (+36.3% vs. FY2024 revenue of $154.5M , and +20.1% cumulative change since FY2023) , GAAP net income of -$68.7M, operating cash flow of -$64.8M, and free cash flow of -$64.9M (-130.6% YoY). On the balance sheet, ZURA closed FY2025 with $113.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$210.7M	-$68.7M	-$64.8M	-$64.9M	$113.9M	—
FY2024 (FY)	2024-12-31	$154.5M	-$52.4M	-$28.1M	-$28.2M	$179.5M	—
FY2023 (FY)	2023-12-31	$175.4M	-$60.4M	-$15.1M	-$15.1M	—	—

3. ZURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZURA compare to PROK and TECX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZURA?

Where is ZURA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZURA last traded at $3.94 (-2.47% on volume of 3,722,536 shares), positioning the stock -13.97% below its 50-day simple moving average ($4.58) and -24.67% below its 200-day simple moving average ($5.23). Across its 52-week range of $3.25 to $7.44, ZURA sits at the 16.5% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.45 to $4.43).

Direct Sub-Reports: ZURA RQD Cockpit ZURA 12M Forecast ZURA Earnings & Move ZURA Dividends & DRIP ZURA Insiders & 13F ZURA Whale Options ZURA Profit Sankey ZURA News & Why

ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZURA — Zura Bio Limited (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:32Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ZURA scores 29 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars each carry a maximum of 20 points. Fundamental Cash Engine scores 5/20, reflecting ROIC of -35% and an FCF yield of -17.51%. Whale 13F Flow scores 5/20, covering institutional accumulation and options positioning. Insider Conviction scores 3/20, covering SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 6/20, reflecting a Beta of 1.0 and sector sensitivity. Forensic Balance Sheet scores 10/20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the pillar profile indicates that the weakest areas are cash generation and insider conviction, while the balance sheet is the relatively stronger component. The rating's verdict is negative on a forensic and risk basis, and the data presented here is educational rather than a recommendation.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zura Bio Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances)..4B. Reported revenue is — in each of the listed fiscal years. — for product lines, customer base, or revenue model detail.

Operating and net losses are reported in each period, with FY 2025 showing the largest operating loss in the table. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Debt/Equity is 0.5. Reported cash declined from $176.5M in FY 2024 to $109.4M in FY 2025.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The balance sheet scores 10/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash of $109.4M remains above zero. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield -17.51%) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $3.25 – $7.44 52-week range.
🐻 Primary Bear Case: The company reports zero revenue, a -35% ROIC, a -17.51% FCF yield, and an RQD verdict of Strong Sell with an RQD score of 29. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ZURA carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: How does the company plan to fund operations, given reported FY 2025 free cash flow of -$64.9M and cash declining to $109.4M?
Key Question #2: What are the intended uses of proceeds from the up-to-$700 million securities offering referenced in the news wire?
Key Question #3: How sensitive is ZURA's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?

ZURA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zura Bio Limited (Class A) (ZURA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZURA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

This biotech stock is a top pick at Guggenheim

Yahoo Finance report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

Zura Bio Limited Estimates – NASDAQ:ZURA

TradingView report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 8K Zura Bio Limited For: 27 October By Investing.com

Investing.com UK report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Quiver Quantitative • 1d ago

Zura Bio Reports $25.8 Million Third-Quarter 2026 Net Loss

Quiver Quantitative report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE scanx.trade • 1d ago

Zura Bio files prospectus to offer up to $700 million in securities

scanx.trade report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Zura Bio presents Phase 2 poster: Guggenheim targets Zura Bio stock at USD 20

ad-hoc-news.de report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH scanx.trade • 1d ago

Zura Bio Q3 Results: Loss narrows 4.76% YoY to $(0.20) per share

scanx.trade report covering Zura Bio Limited (Class A) (ZURA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZURA Bull vs. Bear Conversation Board — What's Your Call at $3.94?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZURA 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $5.33 (+31.9%)

📌 Pinned Debate

The balance sheet scores 10/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash of $109.4M remains above zero.

Long ZURA at $4.04 targeting $5.33. The balance sheet scores 10/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash of $109.4M remains above zero.. Institutional whale score is 5/20 and the risk/reward vs. the $3.25 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $4.04 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $3.07 (-24.0%)

Spot @ $4.04

The company reports zero revenue, a -35% ROIC, a -17.51% FCF yield, and an RQD verdict of Strong Sell with an RQD score of 29.

Sitting on the sidelines or leaning short ZURA above $4.04. The company reports zero revenue, a -35% ROIC, a -17.51% FCF yield, and an RQD verdict of Strong Sell with an RQD score of 29.. Until Fundamental Cash Engine (5/20) and FCF yield (-17.51%) inflect higher, upside is capped near $7.44.